Perioperative statin therapy

Expert Opinion on Pharmacotherapy

Volumn 14, Issue 7, 2013, Pages 831-842

  Chan, Wales W N ^a   Wong, Gordon T C ^b   Irwin, Michael G ^b  

^a QUEEN MARY HOSPITAL   (Hong Kong)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Perioperative; Pleiotropic; Statin; Surgery

Indexed keywords

ALANINE AMINOTRANSFERASE; ATORVASTATIN; BISOPROLOL; CERIVASTATIN; CREATINE KINASE; FLUINDOSTATIN; ISOPRENOID; MEVINOLIN; NITRIC OXIDE; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ACUTE KIDNEY FAILURE; AMNESIA; ATHEROSCLEROTIC PLAQUE; BREAST CANCER; CANCER GROWTH; CANCER MORTALITY; CANCER RISK; CANCER STAGING; CHOLESTEROL SYNTHESIS; CONFUSION; COST EFFECTIVENESS ANALYSIS; DIABETIC PATIENT; DRUG WITHDRAWAL; ELECTIVE SURGERY; GLUCOSE BLOOD LEVEL; HEART ATRIUM FIBRILLATION; HEART DEATH; HEART MUSCLE ISCHEMIA; HEART SURGERY; HIGH RISK PATIENT; HUMAN; LENGTH OF STAY; LIVER CANCER; LIVER FAILURE; META ANALYSIS; MORBIDITY; MUSCLE WEAKNESS; MYALGIA; MYOPATHY; OXIDATIVE STRESS; PERIOPERATIVE PERIOD; PHASE 3 CLINICAL TRIAL (TOPIC); POSTOPERATIVE COMPLICATION; PROSTATE CANCER; PROTEIN PHOSPHORYLATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REPERFUSION INJURY; RETROSPECTIVE STUDY; REVIEW; RHABDOMYOLYSIS; SIDE EFFECT; STATISTICAL SIGNIFICANCE; STOMACH CANCER; SURGICAL MORTALITY; SYSTEMATIC REVIEW; THORAX SURGERY; UTERUS CANCER; VEIN THROMBOSIS;

ACUTE KIDNEY INJURY; ATRIAL FIBRILLATION; BLOOD PLATELETS; CARDIOVASCULAR SURGICAL PROCEDURES; COST-BENEFIT ANALYSIS; ENDOTHELIAL CELLS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INFLAMMATION MEDIATORS; LIPIDS; MUSCLE, SMOOTH, VASCULAR; NEOPLASMS; PERIOPERATIVE PERIOD; POSTOPERATIVE COMPLICATIONS; RISK FACTORS; THROMBOSIS;

EID: 84876063978     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2013.782003     Document Type: Review

References (45)

1. Liao JK, Laufs U. Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol 2005;45:89-118
2. Durazzo AE, Machado FS, Ikeoka DT, et al. Reduction in cardiovascular events after vascular surgery with atorvastatin: a randomized trial. J Vasc Surg 2004;39(5):967-75
3. Schouten O, Kertai MD, Bax JJ, et al. Safety of perioperative statin use in high-risk patients undergoing major vascular surgery. Am J Cardiol 2005;95(5):658-60
4. Schouten O, Boersma E, Hoeks SE, et al. Fluvastatin and perioperative events in patients undergoing vascular surgery. N Engl J Med 2009;361(10):980-9
5. Abbruzzese TA, Havens J, Belkin M, et al. Statin therapy is associated with improved patency of autogenous infrainguinal bypass grafts. J Vasc Surg 2004;39(6):1178-85
6. Henke PK, Blackburn S, Proctor MC, et al. Patients undergoing infrainguinal bypass to treat atherosclerotic vascular disease are underprescribed cardioprotective medications: effect on graft patency, limb salvage, and mortality. J Vasc Surg 2004;39(2):57-65
7. Raux M, Cochennec F, Becquemin JP. Statin therapy is associated with aneurysm sac regression after endovascular aortic repair. J Vasc Surg 2012;55(6):1587-92
8. Dunkelgrun M, Boersma E, Schouten O, et al. Bisoprolol and fluvastatin for the reduction of perioperative cardiac mortality and myocardial infarction in intermediate-risk patients undergoing non cardiovascular surgery: a randomized controlled trial (DECREASE-IV). Ann Surg 2009;249(6):921-6
9. Lindenauer PK, Pekow P, Wang K, et al. Lipid-lowering therapy and in-hospital mortality following major noncardiac surgery. JAMA 2004;291(17):2092-9
10. Hindler K, Shaw AD, Samuels J, et al. Improved postoperative outcomes associated with preoperative statin therapy. Anesthesiology 2006;105(6):1260-72; quiz 1289-90
11. Chopra V, Wesorick DH, Sussman JB, et al. Effect of perioperative statins on death, myocardial infarction, atrial fibrillation, and length of stay: a systematic review and meta-analysis. Arch Surg 2012;147(2):181-9
12. Lee YL, Blaha MJ, Jones SR. Statin therapy in the prevention and treatment of atrial fibrillation. J Clin Lipidol 2011;5(1):18-29
13. Bhave PD, Goldman LE, Vittinghoff E, et al. Incidence, predictors, and outcomes associated with postoperative atrial fibrillation after major noncardiac surgery. Am Heart J 2012;164(6):918-24
14. Molnar AO, Coca SG, Devereaux PJ, et al. Statin use associates with a lower incidence of acute kidney injury after major elective surgery. J Am Soc Nephrol 2011;22(5):939-46
15. Brunelli SM, Waikar SS, Bateman BT, et al. Preoperative statin use and postoperative acute kidney injury. Am J Med 2012;125(12):1195-204; e3
16. Argalious MY, Dalton JE, Sreenivasalu T, et al. The association of preoperative statin use and acute kidney injury after noncardiac surgery. Anesth Analg 2013; Epub ahead of print
17. Argalious M, Xu M, Sun Z, et al. Preoperative statin therapy is not associated with a reduced incidence of postoperative acute kidney injury after cardiac surgery. Anesth Analg 2010;111(2):324-30
18. Argalious MY, Dalton JE, Cywinski JB, et al. Association between preoperative statin therapy and postoperative change in glomerular filtration rate in endovascular aortic surgery. Br J Anaesth 2012;109(2):161-7
19. Moulakakis KG, Matoussevitch V, Borgonio A, et al. Evidence that statins protect renal function during endovascular repair of AAAs. Eur J Vasc Endovasc Surg 2010;40(5):608-15
20. Grady D, Wenger NK, Herrington D, et al. Postmenopausal hormone therapy increases risk for venous thromboembolic disease. The Heart and Estrogen/progestin Replacement Study. Ann Intern Med 2000;132(9):689-96
21. Ray JG, Mamdani M, Tsuyuki RT, et al. Use of statins and the subsequent development of deep vein thrombosis. Arch Intern Med 2001;161(11):1405-10
22. Ramcharan AS, Van Stralen KJ, Snoep JD, et al. HMG-CoA reductase inhibitors, other lipid-lowering medication, antiplatelet therapy, and the risk of venous thrombosis. J Thromb Haemost 2009;7(4):514-20
23. Doggen CJ, Lemaitre RN, Smith NL, et al. HMG CoA reductase inhibitors and the risk of venous thrombosis among postmenopausal women. J Thromb Haemost 2004;2(5):700-1
24. Lacut K, Oger E, Le Gal G, et al. Statins but not fibrates are associated with a reduced risk of venous thromboembolism: a hospital-based casecontrol study. Fundam Clin Pharmacol 2004;18(4):477-82
25. Sorensen HT, Horvath-Puho E, Søgaard KK, et al. Arterial cardiovascular events, statins, low-dose aspirin and subsequent risk of venous thromboembolism: a population-based case-control study. J Thromb Haemost 2009;7(4):521-8
26. Glynn RJ, Danielson E, Fonseca FAH, et al. A randomized trial of rosuvastatin in the prevention of venous thromboembolism. N Engl J Med 2009;360(18):1851-61
27. Goldstein MR, Mascitelli L. Surgery and cancer promotion: are we trading beauty for cancer? QJM 2011;104(9):811-15
28. Xiao H, Yang CS. Combination regimen with statins and NSAIDs: a promising strategy for cancer chemoprevention. Int J Cancer 2008;123(5):983-90
29. Zhuang L, Kim J, Adam RM, et al. Cholesterol targeting alters lipid raft composition and cell survival in prostate cancer cells and xenografts. J Clin Invest 2005;115(4):959-68
30. Malenda A, Skrobanska A, Issat T, et al. Statins impair glucose uptake in tumor cells. Neoplasia 2012;14(4):311-23
31. Garwood ER, Kumar AS, Baehner FL, et al. Fluvastatin reduces proliferation and increases apoptosis in women with high grade breast cancer. Breast Cancer Res Treat 2010;119(1):137-44
32. Lee J, Lee SH, Hur KY, et al. Statins and the risk of gastric cancer in diabetes patients. BMC Cancer 2012;12:596
33. Nielsen SF, Nordestgaard BG, Bojesen SE. Statin Use and reduced cancer-related mortality. N Eng J Med 2012;367(19):1792-802
34. Leung HW, Chan AL, Lo D, et al. Common cancer risk and statins: a population-based case-control study in a Chinese population. Expert Opin Drug Saf 2013;12(1):19-27
35. Boudreau DM, Yu O, Johnson J. Statin use and cancer risk: a comprehensive review. Expert Opin Drug Saf 2010;9(4):603-21
36. Laisalmi-Kokki M, Tolonen K, Miettinen H, et al. Perioperative chronic use of statins and the risk of muscle complaints in patients undergoing knee and hip endoprosthesis surgery. J Clin Anesth 2010;22(2):81-7
37. Omar MA, Wilson JP, Cox TS. Rhabdomyolysis and HMG-CoA reductase inhibitors. Ann Pharmacother 2001;35(9): 1096-107
38. Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. JAMA 2003;289(13):1681-90
39. FDA Drug Safety Communication: important safety label changes to cholesterol-lowering statin drugs. Available from: http://www.fda.gov/Drugs/ DrugSafety/ucm293101.htm [Cited 12th February 2013]
40. Le Manach Y, Godet G, Coriat P, et al. The impact of postoperative discontinuation or continuation of chronic statin therapy on cardiac outcome after major vascular surgery. Anesth Analg 2007;104(6):1326-33; table of contents
41. Schouten O, Hoeks SE, Welten GM, et al. Effect of statin withdrawal on frequency of cardiac events after vascular surgery. Am J Cardiol 2007;100(2):316-20
42. Fallouh N, Chopra V. Statin withdrawal after major noncardiac surgery: risks, consequences, and preventative strategies. J Hosp Med 2012;7(7):573-9
43. Biccard BM, Sear JW, Foex P. The pharmaco-economics of peri-operative statin therapy. Anaesthesia 2005;60(11):1059-63
44. McNally MM, Agle SC, Parker FM, et al. Preoperative statin therapy is associated with improved outcomes and resource utilization in patients undergoing aortic aneurysm repair. J Vasc Surg 2010;51(6):1390-6
45. Zhou Q, Liao JK. Pleiotropic effects of statins. -Basic research and clinical perspectives. Circ J 2010;74(5):818-26